Antibiotics for inflammatory bowel disease: Do they work?

European Journal of Gastroenterology and Hepatology

Volumn 17, Issue 2, 2005, Pages 145-147

  Guslandi, Mario ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

Ciprofloxacin; Crohn's disease; Metronidazole; Pouchitis; Rifaximin; Ulcerative colitis

Indexed keywords

AZATHIOPRINE; BUDESONIDE; CIPROFLOXACIN; CORTICOSTEROID; COTRIMOXAZOLE; IMMUNOSUPPRESSIVE AGENT; MESALAZINE; METHYLPREDNISOLONE; METRONIDAZOLE; PLACEBO; RIFAXIMIN; SALAZOSULFAPYRIDINE; TOBRAMYCIN; TUBERCULOSTATIC AGENT; VANCOMYCIN;

ANTIBIOTIC THERAPY; ANUS FISTULA; ATYPICAL MYCOBACTERIUM; CROHN DISEASE; DIARRHEA; DIGESTIVE SYSTEM FUNCTION DISORDER; DRUG TOLERABILITY; ENTERITIS; ESCHERICHIA COLI; HUMAN; ILEITIS; ILEUM RESECTION; INTESTINE FLORA; LISTERIA MONOCYTOGENES; LONG TERM CARE; MYCOBACTERIUM PARATUBERCULOSIS; NAUSEA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RASH; REMISSION; REVIEW; SYSTEMATIC REVIEW; TASTE DISORDER; ULCERATIVE COLITIS;

ANTI-BACTERIAL AGENTS; CIPROFLOXACIN; HUMANS; INFLAMMATORY BOWEL DISEASES; METRONIDAZOLE; TREATMENT OUTCOME;

EID: 14844323120     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042737-200502000-00003     Document Type: Review

References (48)

1. Dianda L, Hanby AM, Wright NA, Sebesteny A, Hayday AC, Owen MJ. T-cell receptor-alpha-beta-deficient mice fail to develop colitis in the absence of a microbial environment. Am J Pathol 1997; 150:91-97.
2. Swidsinski A, Ladhoff A, Pernthaler A, Swidsinski S, Loening-Baucke V, Ortner M, et al. Mucosal flora in inflammatory bowel disease. Gastroenterology 2002; 122:44-54.
3. D'Haens GR, Geboes K, Peeters M, Baert F, Penninckx F, Rutgeerts P. Early lesions of recurrent Crohn's disease caused by infusion of intestinal content in excluded ileum. Gastroenterology 1998; 114:262-267.
4. Harper PH, Lee ECG, Kettlewell MGW, Bennett MK, Jewell DP. Role of the fecal stream in the maintenance of Crohn's colitis. Gut 1985; 26:279-284.
5. Duchmann R, Schmitt E, Knoll P. Tolerance exists towards resident intestinal flora in mice but is broken in active inflammatory bowel disease. Clin Exp Immunol 1995; 102:448-455.
6. Giaffer MH, Holdsworth CD, Duerden BI. Virulence properties of Escherichia coli isolated from patients with inflammatory bowel disease. Gut 1992; 33:646-650.
7. Selsik P, Rigottier-Gois L, Gramet G, Sutren M, Pochart P, Marteau P, et al. Alterations of the dominant faecal bacterial groups in patients with Crohn's disease of the colon. Gut 2002; 52:237-242.
8. Chiodini RJ, van Kruiningen HJ, Thayer WR Jr, Merkal RS, Coutu JA. Possible role of mycobacteria in inflammatory bowel disease. An unclassified mycobacterium species isolated from patients with Crohn's disease. Dig Dis Sci 1984; 29:1073-1079.
9. Fidler HM, Mc Fadden A. Infective agents-mycobacteria. In: Kirsner JB, Shorter RG (editors): Inflammatory Bowel Disease, 4th edition, Baltimore: Williams & Wilkins; 1995, pp. 125-131.
10. Fabia R, Ar'Rajab A, Joahnsson ML, Andersson R, Willen R, Jeppson B. Impairment of bacterial flora in human ulcerative colitis and experimental colitis in rats. Digestion 1993; 54:248-255.
11. Ruseler-van-Embden JGH, Scheuten WR, van Lieshout LMC. Pouchitis: result of a microbial imbalance? Gut 1994; 35:658-664.
12. Elliott PR, Forseit T, Darougar S, Treharne JD, Lennard-Jones JE. Chlamydiae and inflammatory bowel disease. Gut 1981; 22:25-27.
13. Blaser MJ, Miller RA, Lacher J, Singleton JW. Patients with active Crohn's disease have elevated serum antibodies to antigens of seven enteric bacterial pathogens. Gastroenterology 1984; 87:888-891.
14. Tamboli CP, Neut C, Desreumaux P, Colombel JF. Dysbiosis in inflammatory bowel disease. Gut 2004; 53:1-4.
15. Davies PS, Rhodes J, Heatley RV, Owen E. Metronidazole in the treatment of chronic proctitis. A controlled study. Gut 1987; 18:680-681.
16. Gilat T, Suissa A, Leitchman G, Delpre G, Pavlotzky M, Grossman A, et al. A comparative study of metronidazole and sulfasalazine in active, non severe ulcerative colitis. J Clin Gastroenterol 1987; 9:415-417.
17. Chapman RW, Selby WS, Jewel DP. Controlled trial of intravenous metronidazole as an adjunct to corticosteroids in severe ulcerative colitis. Gut 1986; 27:1210-1212.
18. Madden MV, McIntyre AS, Nicholls RJ. Double-blind crossover trial of metronidazole versus placebo in chronic unremitting pouchitis. Dig Dis Sci 1994; 39:1193-1196.
19. Shen B, Achkar JP, Lashner BA, Ormsby AH, Remzi FH, Brezinski A, et al. A randomized trial of ciprofloxacin and metronidazole to treat acute pouchitis. Inflamm Bowel Dis 2001; 7:301-305.
20. Mimura T, Rizzello F, Helwig U, Poggioli G, Schreiber C, Talbot IC, et al. Four-week open-label trial of metronidazole and ciprofloxacin for the treatment of recurrent or refractory pouchitis. Aliment Pharmacol Ther 2002; 16:909-917.
21. Bichfeldt P, Blomhoff JP, Myhre E, Gjone E. Metronidazole in Crohn's disease. Scand J Gastroenterol 1978; 13:123-127.
22. Sutherland L, Singleton J, Sessions J, Hanauer S, Krawitt E, Rankin G, et al. Double-blind placebo-controlled trial of metronidazole in Crohn's disease. Gut 1991; 32:1071-1075.
23. Ambrose NS, Allan RN, Keighley MR, Burd DW, Youngs D, Barnes P, et al. Antibiotic therapy for treatment in relapse of intestinal Crohn's disease. A prospective randomized study. Dis Colon Rectum 1985; 28:81-85.
24. Rosen A, Ursing B, Alm T, Barani F, Bergelin I, Ganrot-Norlin K, et al. A comparative study of metronidazole and sulfasalazine for active Crohn's disease: the cooperative Crohn's disease study in Sweden. Gastroenterology 1982; 83:550-562.
25. Prantera C, Zannoni F, Scribano ML, Falarco G. An antibiotic regimen for the treatment of active Crohn's disease: a randomized, controlled trial of metronidazole plus ciprofloxacin. Am J Gastroenterol 1996; 91: 328-332.
26. Rutgeerts P, Hiele M, Geboes K, Peeters M, Pennickx F, Aerts R, et al. Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection. Gastroenterology 1995; 108:1617-1621.
27. Berstein LH, Frank SM, Brandt LJ, Boley SJ. Healing of perineal Crohn's disease with metronidazole. Gastroenterology 1980; 79:357-365.
28. Brandt U, Bernstein LH, Boley SJ, Franks MS. Metronidazole therapy for perineal Crohn's disease: a follow-up study. Gastroenterology 1982; 83:33-37.
29. Jakobivtzs J, Schuster MM. Metronidazole therapy for Crohn's disease and associated fistulae. Am J Gastroenterol 1984; 79:533-540.
30. McKee RF, Keenan RA. Perianal Crohn's disease: is it all bad news? Dis Colon Rectum 1996; 39:136-142.
31. Dejaco C, Harrer M, Waldhoer T, Miehsler W, Vogelsang H, Reinisc W. Antibiotics and azathioprine for the treatment of perianal fistulas in Crohn's disease. Aliment Pharmacol Ther 2003; 18:1113-1120.
32. Turunen UM, Farkkila MA, Hakala K, Seppala K, Sivonen A, Ogren M, et al. Long-term treatment of ulcerative colitis with ciprofloxacin: a prospective double-blind, placebo-controlled study. Gastroenterology 1998; 115: 1072-1078.
33. Mantzaris GJ, Petraki K, Archavlis E, Amberiadis P, Kourtessas D, Christidou A, et al. A prospective randomized controlled trial of intravenous ciprofloxacin as an adjunct to corticosteroids in acute, severe ulcerative colitis. Scand J Gastroenterol 2001; 36:971-974.
34. Hurst RD, Molinari M, Chung TP. Prospective study of the incidence, timing and treatment of pouchitis in 104 consecutive patients after restorative proctocolectomy. Arch Surg 1996; 131:497-500.
35. Solomon MJ, McLeod RS, O'Connor BL. Combination ciprofloxacin and metronidazole in severe perianal Crohn's disease. Can J Gastroenterol 1993; 7:571-572.
36. Greenbloom SL, Steinhart AH, Greenberg GR. Combination ciprofloxacin and metronidazole for active Crohn's disease. Can J Gastroenterol 1998; 12:53-56.
37. Arnold GL, Beaves MR, Pryjdun VO, Mook WJ. Preliminary study of ciprofloxacin in active Crohn's disease. Inflamm Bowel Dis 2002; 8:10-15.
38. Colombel JF, Lemann M, Cassagnou M, Bouknik Y, Duclos B, Dupas JL, et al. A controlled trial comparing ciprofloxacin with mesalazine for the treatment of active Crohn's disease. Am J Gastroenterol 1999; 94:674-678.
39. Prantera C, Berto E, Scribano ML, Falasco G. Use of antibiotics in the treatment of active Crohn's disease: experience with metronidazole and ciprofloxacin. Ital J Gastroenterol Hepatol 1998; 30:602-606.
40. Steinhart AH, Fegan BG, Wong CJ, Vandervoort M, Mikolainis S, Croitoru K, et al. Combined budenoside and antibiotic therapy for active Crohn's disease: a randomized controlled trial. Gastroenterology 2002; 123:33-40.
41. Hulten K, Almashhrawi A, El-Zaatari F, Graham DY. Antibacterial therapy for Crohn's disease: a review emphasizing therapy directed against mycobacteria. Dig Dis Sci 2000; 45:445-446.
42. Dickinson RJ, O'Connor HJ, Pinder I. Double blind controlled trial of oral vancomycin as adjunctive treatment in acute exacerbations of idiopathic colitis. Gut 1985; 26:1380-1384.
43. Burke DA, Axon ATR, Clayden SA, Dixon MF, Johnston D, Lacey RW. The efficacy of tobramycin in the treatment of ulcerative colitis. Aliment Pharmacol Ther 1990; 4:123-129.
44. Gionchetti P, Rizzello F, Ferrieri A, Venturi A, Brignola C, Ferretti M, et al. Rifaximin in patients with moderate or severe ulcerative colitis refractory to steroid treatment: a double-blind placebo-controlled trial. Dig Dis Sci 1999; 44:1220-1221.
45. Gusland M, Giollo P, Testoni PA. Corticosteroid-sparing effect of rifaximin, a nonabsorbable oral antibiotic, in active ulcerative colitis: preliminary clinical experience. Curr Ther Res Clin Exp 2004; 65:292-296.
46. Shafran I, Johnson LK, Hamm L, Murdocj RH. Efficacy and tolerability of rifaximin, a nonabsorbed oral antibiotic, in the treatment of active Crohn's disease: results of an open-label study. Am J Gastroenterol 2003; 98 (suppl):S250.
47. Gionchetti P, Rizzello F, Venturi A, Ugolini F, Rossi M, Brigidi P, et al. Antibiotic combination therapy in patients with chronic treatment-resistant pouchitis. Aliment Pharmacol Ther 1999; 13:713-718.
48. Hoentjen F, Harmsen HJM, Braat H, Torrice CD, Mann BA, Sartor RB, et al. Antibiotics with a selective aerobic or anaerobic spectrum have different therapeutic activities in various regions of the colon in interleukin 10 gene deficient mice. Gut 2003; 52:1721-1727.